Downloads: 0 | Views: 141

Review Papers | Cancer Science | India | Volume 11 Issue 10, October 2022 | Popularity: 4.4 / 10

Rate This Article!      

Remedial Magic of Dostarlimab in Endometrium Cancer

Mitushi Singh, Gorika Tomar, Isha Sharma, Prashant Mathur

Abstract: Endometrial cancer can be cured if we can diagnosed it early, even after that 0.88 million cases were found in India with an incident rate of 105.5 per 100, 000 in women. Immunotherapy is one of the most effective and convenient method used in the treatment of cancer. It includes immune checkpoint inhibitors therapy, monoclonal antibody therapy for example anti-programmed cell death proteinPD-1 receptor monoclonal antibody (Dostarlimab), antigen T-cell therapy. Immunotherapy works on the cancer cells by making their progression decline and controls the growth of cells. In this review, we discussed the mechanism of Dostarlimab in the endometrial cancer mainly. We also discussed the different trials that were going out with the drug Dostarlimab and the pharmacokinetic and pharmacodynamic of the drug which helps in the better understanding of the drug in terms of its evolution after the large number of trials in humans and other living organism also.

Keywords: Immunotherapy, Programmed cell death protein receptor, Endometrial cancer

Edition: Volume 11 Issue 10, October 2022

Pages: 1106 - 1110

DOI: https://www.doi.org/10.21275/SR221019224956

Make Sure to Disable the Pop-Up Blocker of Web Browser

Click to Cite this Article

Similar Articles